Table 1.
Analysis of general clinical conditions of 213 patients with acute myocardial infarction
| All (n = 213) | Genotype | P value | ||||
|---|---|---|---|---|---|---|
| Arg389Arg (n = 140) | Arg389Gly (n = 46) | Gly389Gly (n = 27) | ||||
| Male | 147 (69.01%) | 100 (71.43%) | 30 (65.22%) | 17 (63.96%) | 0.562 | |
| Age (years) | 56.01 ± 13.38 | 56.11 ± 12.81 | 56.35 ± 13.98 | 54.89 ± 15.53 | 0.893 | |
| Smoking | 115 (53.99%) | 77 (55.00%) | 23 (50.00%) | 15 (55.56%) | 0.827 | |
| Alcohol | 50 (23.47%) | 31 (22.14%) | 10 (21.74%) | 9 (33.33%) | 0.433 | |
| Essential hypertension | 127 (59.62%) | 86 (61.43%) | 28 (60.87%) | 13 (48.15%) | 0.428 | |
| Diabetes | 56 (26.29%) | 40 (28.57%) | 10 (21.74%) | 6 (22.22%) | 0.577 | |
| Coronary heart disease | 22 (10.33%) | 17 (12.14%) | 3 (6.52%) | 2 (7.41%) | 0.590 | |
| Healed myocardial infarction | 7 (3.27%) | 5 (3.57%) | 1 (2.17%) | 1 (3.70%) | >0.999 | |
| CKD | 15 (7.04%) | 10 (7.14%) | 2 (4.35%) | 3 (11.11%) | 0.555 | |
| Onset time | 9.59 ± 3.69 | 9.61 ± 3.68 | 9.35 ± 3.76 | 9.89 ± 3.70 | 0.827 | |
| Chest pain | 113 (53.1%) | 73 (52.1%) | 24 (52.2%) | 16 (59.3%) | 0.787 | |
| Site | Anterior | 57 (26.76%) | 35 (25.00%) | 12 (21.09%) | 10 (37.04%) | 0.541 |
| Inferior | 36 (16.90%) | 26 (18.57%) | 8 (17.39%) | 2 (7.41%) | ||
| High lateral | 13 (6.10%) | 10 (7.14%) | 1 (2.17%) | 2 (7.41%) | ||
| Other | 7 (3.29%) | 3 (2.14%) | 3 (6.52%) | 1 (3.70%) | ||
| NSTEMI | 100 (46.95%) | 66 (47.14%) | 22 (47.83%) | 12 (44.44%) | ||
| Emergency PCI | 192 (90.14%) | 130 (92.86%) | 39 (84.78%) | 23 (85.19%) | 0.161 | |
| Culprit vessel | LM | 3 (1.41%) | 2 (1.43%) | 0 (0.00%) | 1 (3.70%) | 0.155 |
| LAD | 106 (49.77%) | 63 (45.00%) | 25 (54.75%) | 18 (66.67%) | ||
| RCA | 82 (38.50%) | 57 (40.71%) | 19 (41.30%) | 6 (22.22%) | ||
| LCX | 22 (10.33%) | 18 (12.86%) | 2 (4.35%) | 2 (7.41%) | ||
| Antiplatelet | A + T | 170 (79.81%) | 113 (80.71%) | 39 (84.78%) | 18 (66.67%) | 0.254 |
| A + C | 39 (18.31%) | 24 (17.14%) | 6 (13.04%) | 9 (33.33%) | ||
| Other | 4 (1.88%) | 3 (2.14%) | 1 (2.17%) | 0 (0.00%) | ||
| Statin | 210 (98.59%) | 138 (98.57%) | 46 (100.00%) | 26 (96.30%) | 0.436 | |
| Metoprolol | 0 mg | 56 (26.29%) | 38 (28.14%) | 10 (21.74%) | 8 (29.63%) | 0.215 |
| 23.75 mg | 115 (53.99%) | 69 (49.29%) | 29 (63.04%) | 17 (62.96%) | ||
| 47.5 mg | 42 ((19.72%) | 33 (23.59%) | 7 (15.22%) | 2 (7.41%) | ||
| Average dose of metoprolol | 22.19 ± 16.07 | 22.90 ± 16.95 | 22.20 ± 14.51 | 18.47 ± 13.71 | 0.425 | |
| Admission heart rate | 77.85 ± 8.69 | 79.66 ± 9.10 | 75.46 ± 6.98 | 72.6 ± 5.58 | <0.001 | |
| Mechanical complications | 2 (0.94%) | 1 (0.71%) | 1 (2.17%) | 0 (0.00%) | 0.569 | |
| Recurrent MI | 2 (0.94%) | 2 (1.43%) | 0 (0.00%) | 0 (0.00%) | >0.999 | |
| Acute cardiac insufficiency | 13 (6.10%) | 9 (6.43%) | 3 (6.52%) | 1 (3.70%) | 0.923 | |
| Hospital stay time | 10.43 ± 2.97 | 10.36 ± 3.03 | 10.67 ± 3.18 | 10.37 ± 2.22 | 0.824 | |
| Heart rate when out of CCU | 69.62 ± 5.53 | 70.06 ± 6.00 | 69.20 ± 4.50 | 68.07 ± 4.23 | 0.197 | |
| Death | 12 (5.63%) | 9 (6.43%) | 3 (6.52%) | 0 (0.00%) | 0.495 | |
A + C, Aspirin + Clopidogrel; A + T, Aspirin + Ticagrelor; CCU, coronary care unit; CKD, chronic kidney disease; LAD, left anterior descending; LCX, left circumflex; LM, left main; MI, myocardial infarction; NSTEMI, non ST segment elevation myocardial infarction; PCI, percutaneous coronary intervention; RCA, right coronary artery.